Suchergebnisse - "Cook, Gordon"

PubPharm (409)

31

Defining FiTNEss for treatment for multiple myeloma

enthalten in: The lancet. Healthy longevity | 2022

von Cook, G. | Pawlyn, C. | Cairns, D. | +1

CommentOn: BMJ Open. 2022 Jun 2;12(6):e056147. - PMID 35654466

32

Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study

enthalten in: Bone marrow transplantation | 2022

von Snowden, J. | Ahmedzai, S. | Cox, A. | +10

33

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma : A European Myeloma Network (EMN) Report Within the HARMONY Project

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von D'Agostino, M. | Cairns, D. | Lahuerta, J. | +28

ErratumIn: J Clin Oncol. 2022 Dec 1;40(34):4032. - PMID 36260864

34

Immune senescence in multiple myeloma-a role for mitochondrial dysfunction?

enthalten in: Leukemia | 2022

von Seymour, F. | Carmichael, J. | Taylor, C. | +2

35

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma : Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von de Tute, R. | Pawlyn, C. | Cairns, D. | +14

CommentIn: J Clin Oncol. 2022 Sep 1;40(25):2863-2866. - PMID 35772041

36

The Beaker Phenomenon and the Genomic Transformation of Northwest Europe

enthalten in: bioRxiv.org | 2022

von Olalde, I. | Brace, S. | Allentoft, M. | +100

37

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

enthalten in: Transplantation and cellular therapy | 2022

von Dhakal, B. | Shah, N. | Kansagra, A. | +34

38

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)) : a study protocol for a randomised phase III trial

enthalten in: BMJ open | 2022

von Coulson, A. | Royle, K. | Pawlyn, C. | +22

CommentIn: Lancet Healthy Longev. 2022 Nov;3(11):e729-e730. - PMID 36356621

39

Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response

enthalten in: bioRxiv.org | 2022

von Ramasamy, K. | Sadler, R. | Jeans, S. | +17

40

Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response

enthalten in: British journal of haematology | 2022

von Ramasamy, K. | Sadler, R. | Jeans, S. | +17